To determine whether the anti-proliferative activity of niraparib could be enhanced by PRMT5 inhibition, we evaluated the anti-proliferative effects of the combination on homologous recombination proficient breast and ovarian cancer cell lines. Here, PRMT5 is linked to ovarian cancer.